What is Setmelanotide (Imcivree) used for?
Setmelanotide (Imcivree) is most commonly used for patients with diagnosed monogenic obesity (POMC, PCSK1, LEPR, BBS); educational reference for the MC4R pathway; researchers studying the melanocortin / hypothalamic appetite axis. A weight-loss drug for rare genetic forms of obesity. An MC4R agonist, FDA-approved in 2020 for obesity due to POMC, PCSK1, or LEPR deficiency and in 2022 for Bardet-Biedl syndrome; it's the educational anchor for melanocortin-pathway weight regulation. Human evidence for Setmelanotide (Imcivree) is limited, so these are the goals people pursue with it, not guaranteed outcomes.
What people use Setmelanotide (Imcivree) for
- Patients with diagnosed monogenic obesity (POMC, PCSK1, LEPR, BBS)
- Educational reference for the MC4R pathway
- Researchers studying the melanocortin / hypothalamic appetite axis
References
- Setmelanotide for Obesity due to LEPR or POMC deficiency — Clément K et al., Lancet Diabetes Endocrinol, 2020
- Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome: a phase 3 trial — Haqq AM et al., The Lancet Diabetes & Endocrinology, 2022
- Imcivree (setmelanotide) — Drugs@FDA approval record (ApplNo 213793) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Setmelanotide (Imcivree)
Full Setmelanotide (Imcivree) breakdownSetmelanotide (Imcivree) side effectsSetmelanotide (Imcivree) how to take itSetmelanotide (Imcivree) mistakes to avoidSetmelanotide (Imcivree) who should avoid itSetmelanotide (Imcivree) half-lifeSetmelanotide (Imcivree) how long to workSetmelanotide (Imcivree) legal statusSetmelanotide (Imcivree) how it worksAsk the AI Coach
Last updated 2026-06-15.